SCHEMBL15380722

SCHEMBL15380722

CC1(C)CCNS1(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31310067 0.84
SCHEMBL21911281 0.72
SCHEMBL22739143 0.70
SCHEMBL21445359 0.69
SCHEMBL11995858 0.60
SCHEMBL35211519 0.59
SCHEMBL576859 0.59
SCHEMBL11995857 0.58
SCHEMBL22924902 0.57
SCHEMBL13319142 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079878-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof 2026-05-26 CN disclosed
CN-122079879-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof 2026-05-26 CN disclosed
CN-122079880-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof 2026-05-26 CN disclosed
US-20260085045-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2026-03-26 US disclosed
US-12497366-B2 Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-12-16 US disclosed
US-20250326722-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2025-10-23 US disclosed
EP-4588914-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2025-07-23 EP disclosed
CN-120019043-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2025-05-16 CN disclosed
CN-119264042-A Cyclopentane derivative-containing inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2025-01-07 CN disclosed
WO-2024078620-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2024-04-18 WO disclosed
US-9775845-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2017-10-03 US disclosed
US-20160200732-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2016-07-14 US disclosed
US-20160200732-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2016-07-14 US disclosed
US-9265772-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2016-02-23 US disclosed
US-9265772-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2016-02-23 US disclosed
CN-104640856-A Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS INC 2015-05-20 CN disclosed
EP-2855458-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Reset Therapeutics, Inc. (US) 2015-04-08 EP disclosed
WO-2013170186-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS, INC. (US) 2013-11-14 WO disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 US disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 US disclosed